David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.9B |
| 2 |
Broadcom
AVGO
|
+$1.07B |
| 3 |
NVIDIA
NVDA
|
+$908M |
| 4 |
Meta Platforms (Facebook)
META
|
+$861M |
| 5 |
Intuitive Surgical
ISRG
|
+$666M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.68B |
| 2 |
Apple
AAPL
|
+$1.31B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$789M |
| 4 |
GE Aerospace
GE
|
+$653M |
| 5 |
Applovin
APP
|
+$634M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.25% |
| 2 | Consumer Discretionary | 7.51% |
| 3 | Financials | 7.11% |
| 4 | Healthcare | 6.95% |
| 5 | Industrials | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Mercado Libre
MELI
$97.5B
| $155M | 0.09% |
66,237
+17,990
| +37% | +$43.2M |
|
252
Vaxcyte
PCVX
$9.32B
| $155M | 0.09% |
4,290,790
+1,202,340
| +39% | +$39.8M |
|
253
Aurora
AUR
$12.5B
| $154M | 0.09% |
28,655,175
+14,718,028
| +106% | +$86.3M |
|
254
CALL
Procter & Gamble
PG
$336B
| $154M | 0.09% |
1,005,200
+581,500
| +137% | +$90.8M |
|
255
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.7B
| $154M | 0.09% |
1,617,500
-76,900
| -5% | -$7.2M |
|
256
PUT
Strategy Inc
MSTR
$47.4B
| $154M | 0.09% |
477,300
+327,300
| +218% | +$121M |
|
257
First Citizens BancShares
FCNCA
$24.7B
| $152M | 0.09% |
84,708
+51,403
| +154% | +$101M |
|
258
Tenet Healthcare
THC
$22.6B
| $151M | 0.09% |
744,896
-63,358
| -8% | -$11.2M |
|
259
PUT
Booking.com
BKNG
$158B
| $151M | 0.09% |
700,000
| – | – |
|
260
TeraWulf
WULF
$7.8B
| $150M | 0.08% |
+13,175,589
| New | +$101M |
|
261
Pfizer
PFE
$160B
| $150M | 0.08% |
5,903,798
+2,154,868
| +57% | +$53.2M |
|
262
Charles River Laboratories
CRL
$14.1B
| $150M | 0.08% |
959,537
+352,518
| +58% | +$56M |
|
263
Ferguson
FERG
$46.9B
| $150M | 0.08% |
+667,316
| New | +$151M |
|
264
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.4B
| $149M | 0.08% |
2,807,200
+25,400
| +0.9% | +$1.34M |
|
265
DexCom
DXCM
$34.8B
| $148M | 0.08% |
2,203,487
+241,897
| +12% | +$19.1M |
|
266
Bank of Montreal
BMO
$122B
| $148M | 0.08% |
1,135,007
-261,221
| -19% | -$30.9M |
|
267
Liberty Media Series C
FWONK
$26.3B
| $148M | 0.08% |
1,412,886
+23,194
| +2% | +$2.35M |
|
268
Chubb
CB
$132B
| $147M | 0.08% |
520,004
+386,395
| +289% | +$106M |
|
269
PUT
Scotiabank
BNS
$107B
| $146M | 0.08% |
2,256,200
+1,535,000
| +213% | +$90.5M |
|
|
JBS
270
JBS N.V.
JBS
$45.5B
| $145M | 0.08% |
9,727,691
+8,571,831
| +742% | +$125M |
|
271
PUT
CVS Health
CVS
$119B
| $145M | 0.08% |
1,919,000
+118,600
| +7% | +$8.13M |
|
272
PUT
United Airlines
UAL
$36.7B
| $144M | 0.08% |
1,493,600
+208,000
| +16% | +$20M |
|
|
SNDK
273
Sandisk
SNDK
$234B
| $144M | 0.08% |
1,283,560
+1,229,885
| +2,291% | +$71.8M |
|
274
PUT
Zscaler
ZS
$29.4B
| $143M | 0.08% |
478,800
+309,800
| +183% | +$88.3M |
|
275
CALL
ASML
ASML
$677B
| $143M | 0.08% |
148,000
+62,500
| +73% | +$49.1M |
|
Similar funds
David Shaw's Q3 2025 Portfolio in Review
As of Q3 2025, David Shaw held 5,023 positions worth $177B, up 26% from $141B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
David Shaw deployed $15.2B of net new capital in Q3 2025, opening 714 new positions and adding to 1,743 existing holdings. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 3,319,000 shares worth $370M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.68B trimmed.
- David Shaw's largest Q3 2025 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 3,319,000 shares worth $370M.
- David Shaw added most to Microsoft in Q3 2025, an estimated $1.9B increase.
- David Shaw's biggest Q3 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.68B.
- David Shaw fully exited Hess in Q3 2025, selling an estimated $527M.
- David Shaw's ten largest holdings make up 13% of its $177B portfolio in Q3 2025.
- David Shaw opened 714 new positions and closed 514 in Q3 2025.
- David Shaw's portfolio value rose 26% quarter-over-quarter to $177B.
Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.